TherapeuticsMD Vice President of Business Development Named Finalist in 16th Annual Stevie® Awards for Women in Business
October 10 2019 - 5:45AM
Business Wire
Jennifer Wilson Recognized as a Finalist for
Female Executive of the Year
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s
healthcare company, today announced that Jennifer Wilson, Vice
President of Business Development, has been named a Finalist
in the Female Executive of the Year – Business Products category in
the 16th annual Stevie® Awards for Women in Business.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191010005098/en/
Jennifer Wilson VP of Business
Development, TXMD. (Photo: Business Wire)
The Stevie Awards for Women in Business honor women executives,
entrepreneurs, employees and the companies they run – worldwide.
The Stevie Awards have been hailed as the world’s premier business
awards.
Finalists were determined by the average scores of more than 150
business professionals around the world, working on seven juries.
Their scores will also determine the Gold, Silver, and Bronze
Stevie Award placements that will be revealed at the 16th annual
awards dinner and presentations in New York.
“We are incredibly proud of the contributions Jennifer has made
to TherapeuticsMD which has led to continued business growth and
increased awareness for our products,” said TherapeuticsMD
Co-Founder and Chief Executive Officer Robert Finizio. “We
congratulate Jennifer and believe that she will play an integral
role in furthering our mission to empower women with innovative
solutions that address previously unmet needs at every phase of
their life.”
“In its sixteenth year, the Stevie Awards for Women in Business
received a record number of nominations. With the second annual
Women|Future Conference preceding the announcement of winners on
Nov. 15, it will be a day to celebrate the achievements of working
women around the world,” said Michael Gallagher, founder and
Executive Chairman of the Stevie Awards. “We’re looking forward to
recognizing the Stevie Award winners next month.”
This year’s Stevie Awards for Women in Business event will be
complemented by a two-day educational and networking conference
called the Women|Future Conference, also at the Marriott Marquis
Hotel on November 14-15, 2019.
Details about the Stevie Awards for Women in Business and the
list of Finalists in all categories are available at
www.StevieAwards.com/Women.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the
unique changes and challenges women experience through the various
stages of their lives with a therapeutic focus in family planning,
reproductive health, and menopause management. The company is
committed to advancing the health of women and championing
awareness of their healthcare issues. To learn more about
TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on
Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that the company intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as “believes,” “hopes,”
“may,” “anticipates,” “should,” “intends,” “plans,” “will,”
“expects,” “estimates,” “projects,” “positioned,” “strategy” and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled “Risk Factors” in
the company’s filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, and include
the following: the company’s ability to maintain or increase sales
of its products; the company’s ability to develop and commercialize
IMVEXXY®, ANNOVERA™, BIJUVA® and its hormone therapy drug
candidates and obtain additional financing necessary therefor;
whether the company will be able to comply with the covenants and
conditions under its term loan facility; the potential of adverse
side effects or other safety risks that could adversely affect the
commercialization of the company’s current or future approved
products or preclude the approval of the company’s future drug
candidates; the length, cost and uncertain results of future
clinical trials; the company’s reliance on third parties to conduct
its manufacturing, research and development and clinical trials;
the ability of the company’s licensees to commercialize and
distribute the company’s products; the availability of
reimbursement from government authorities and health insurance
companies for the company’s products; the impact of product
liability lawsuits; the influence of extensive and costly
government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases
and financial tables can be viewed and downloaded at its website:
www.therapeuticsmd.com/pressreleases.aspx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191010005098/en/
Investor Contact Nichol Ochsner, Vice President Investor
Relations 561-961-1900, ext. 2088 Nochsner@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2024 to May 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From May 2023 to May 2024